Abstract P068: Does ApoE Genotype Modify the Relationship between the Omega-3 Index and Cardiovascular Risk Markers?
Background: Earlier reports indicated that patients with apolipoprotein (apo) ε4 genotype responded to fish oil supplementation with a rise in LDL-C compared to patients with the most common genotype, ε3/ε3 (the reference group). Accordingly, supplementation in this group was discouraged.
Objective: We tested the hypothesis that lipid/lipoprotein and inflammatory biomarker levels in ε4 carriers respond to an increase in n-3 fatty acid intakes differently from the reference group.
Methods: Both cross-sectional and longitudinal analyses were performed using de-identified clinical laboratory data. In the former analysis we included 136,701 patients with data available for apoE genotype, RBC n-3 fatty acids (the Omega-3 Index), lipoprotein-associated phospholipase A2 (Lp-PLA2), triglycerides, and LDL particle number (P). In the latter analysis we included a subset of 13,103 patients with biomarker data available from two visits approximately 4 months apart. A 1.64% increase in the Omega-3 Index was used as a marker of increased n-3 intake between visits (based on past observations in Framingham).
Results: Cross-sectionally, the ε4 carriers had lower Omega-3 Indexes than the reference group, and the same inverse relations were found in all genotypes when comparing these markers across Omega-3 Index categories [low (black), middle (white), and high (grey)] (Figure). Longitudinally, there were significant inverse relations between changes in the Omega-3 Index and changes in biomarkers, and these relations were similar for ε3 homozygotes and ε4 carriers.
Conclusions: Lipoprotein and inflammatory biomarker levels changed in concert with changes in the Omega-3 Index, and these changes were the same in ε4 carriers and in ε3 homozygotes. Because the former have reduced Omega-3 Indexes and an increased risk for coronary heart disease and Alzheimer’s disease (for which n-3 fatty acids may be protective), those with the apoE4 genotype may be the most in need of supplemental omega-3 fatty acids.
- © 2013 by American Heart Association, Inc.